News
Diethylene Glycol (DEG) and Ethylene Glycol (EG) testing on high-risk drug components
Following several global incidents involving contaminated drug products specifically designed for children, the U.S. Food and Drug Administration (FDA) released a guidance document to address the potential danger of diethylene glycol (DEG) and ethylene glycol (...) Read more
Advanced Therapy Medicinal Products: First platform for adeno-associated viruses in gene therapy
In a significant step towards enhancing the field of gene therapy, Kymos has joined forces with the VIRAL VECTOR PRODUCTION UNIT—a collaboration between the Autonomous University of Barcelona and the Vall d'Hebron Research Institute. Together, (...) Read more
One LC-MS/MS method for four Cannabinoids
Cannabis and its medicinal use have long been discussed among the medical community and have been repeatedly called for by patient associations. However, cannabis was illegal in many countries and classified as an abuse drug. (...) Read more
Kymos and Prolytic are CIR certified
In addition to Kymos, which has been CIR certified for quite some time, our German subsidiary Prolytic has been approved a CIR certification as well. Now your R&D activities (from Early Phase up to Phase (...) Read more
